Physician profile
Andrew Cushenbery
NPI 1467958967
$1,627.44
in general payments reported to CMS, 2019-2025
15 companies · $551 in 2025
The $551 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $194 · 2022: $51.00 · 2023: $174 · 2024: $658 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,382.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $502.42 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $366.85 | 2021-2025 | |
| Novo Nordisk INC | $341.89 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Boston Scientific Corporation | $85.51 | 2023-2025 | Innova Vascular, Eluvia, Watchman Flx |
| Amgen INC. | $47.85 | 2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.39 | 2021 | |
| Eisai INC. | $44.75 | 2021 | |
| Dexcom, INC. | $37.46 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $36.76 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $29.72 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $19.44 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $19.14 | 2021 | |
| Glaxosmithkline, LLC. | $18.26 | 2024 | Shingrix, Arexvy |
| Orthofix Medical, INC. | $16.68 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Cushenbery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.